Figure 4 | Scientific Reports

Figure 4

From: Intranasal Delivery of Recombinant AAV Containing BDNF Fused with HA2TAT: a Potential Promising Therapy Strategy for Major Depressive Disorder

Figure 4

The Effects of BDNF-HA2TAT/AAV in CMS Mice.

(A) The Sucrose Consumption Test (SCT): Compared to the control group, the sucrose solution intake gradually decreased due to the CMS onset. (B–D) Behavioral tests of the CMS mice after 10 days administration. The BDNF-HA2TAT/AAV was applied to mice subjected to CMS paradigm and the anti-depressant effects were measured after 10 days of last administration. (B) Open Field Test (OFT): Total distance moved in 1 hour. (C) Tail Suspension Test (TST): Immobility time. (D) Forced Swimming Test (FST): Immobility time. Data are shown as the means ± SEM. *p < 0.05, **p < 0.01.

Back to article page